BIIB:US
$117.21
0.334%
Biogen Inc.News & Events
Last updated: May 8, 2025, 3:50 AM ET
Leqembi®? (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union
GlobeNewswire APR 15, 2025 7:00 PM EDTIn the European Union (EU), lecanemab is indicated for the treatment of adult patients with a cli...READ ARTICLEBiogen's Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer's Disease
GlobeNewswire APR 2, 2025 7:30 AM EDTCAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announc...READ ARTICLEBiogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square
GlobeNewswire MAR 24, 2025 7:30 AM EDTBiogen signs lease for Kendall Common as part of multi-year real estate optimization plan to mode...READ ARTICLEBiogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
GlobeNewswire MAR 11, 2025 7:30 AM EDTGlobal Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared ...READ ARTICLEThe Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease
PR Newswire FEB 28, 2025 8:23 AM ESTThe Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanema...READ ARTICLEBiogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments
GlobeNewswire FEB 18, 2025 8:00 AM ESTStoke retains exclusive rights for zorevunersen in the United States, Canada, and Mexico; Biogen ...READ ARTICLEBiogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments
Business Wire FEB 18, 2025 8:00 AM ESTStoke retains exclusive rights for zorevunersen in the United States, Canada, and Mexico; Biogen ...READ ARTICLEUpdate on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union
GlobeNewswire JAN 31, 2025 6:30 AM ESTTOKYO and CAMBRIDGE, Mass., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Toky...READ ARTICLEFDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
GlobeNewswire JAN 26, 2025 6:33 PM ESTOnce every four weeks maintenance dosing may be easier for patients and care partners to continue...READ ARTICLEFDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
PR Newswire JAN 26, 2025 6:30 PM ESTFDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzh...READ ARTICLE